403 related articles for article (PubMed ID: 25446771)
1. Development and Application of a Mechanistic Pharmacokinetic Model for Simvastatin and its Active Metabolite Simvastatin Acid Using an Integrated Population PBPK Approach.
Tsamandouras N; Dickinson G; Guo Y; Hall S; Rostami-Hodjegan A; Galetin A; Aarons L
Pharm Res; 2015 Jun; 32(6):1864-83. PubMed ID: 25446771
[TBL] [Abstract][Full Text] [Related]
2. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update.
Ramsey LB; Johnson SG; Caudle KE; Haidar CE; Voora D; Wilke RA; Maxwell WD; McLeod HL; Krauss RM; Roden DM; Feng Q; Cooper-DeHoff RM; Gong L; Klein TE; Wadelius M; Niemi M
Clin Pharmacol Ther; 2014 Oct; 96(4):423-8. PubMed ID: 24918167
[TBL] [Abstract][Full Text] [Related]
3. Individual and Combined Associations of Genetic Variants in CYP3A4, CYP3A5, and SLCO1B1 With Simvastatin and Simvastatin Acid Plasma Concentrations.
Luzum JA; Theusch E; Taylor KD; Wang A; Sadee W; Binkley PF; Krauss RM; Medina MW; Kitzmiller JP
J Cardiovasc Pharmacol; 2015 Jul; 66(1):80-5. PubMed ID: 26164721
[TBL] [Abstract][Full Text] [Related]
4. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy.
Wilke RA; Ramsey LB; Johnson SG; Maxwell WD; McLeod HL; Voora D; Krauss RM; Roden DM; Feng Q; Cooper-Dehoff RM; Gong L; Klein TE; Wadelius M; Niemi M;
Clin Pharmacol Ther; 2012 Jul; 92(1):112-7. PubMed ID: 22617227
[TBL] [Abstract][Full Text] [Related]
5. SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid.
Pasanen MK; Neuvonen M; Neuvonen PJ; Niemi M
Pharmacogenet Genomics; 2006 Dec; 16(12):873-9. PubMed ID: 17108811
[TBL] [Abstract][Full Text] [Related]
6. Identification of the effect of multiple polymorphisms on the pharmacokinetics of simvastatin and simvastatin acid using a population-modeling approach.
Tsamandouras N; Dickinson G; Guo Y; Hall S; Rostami-Hodjegan A; Galetin A; Aarons L
Clin Pharmacol Ther; 2014 Jul; 96(1):90-100. PubMed ID: 24598718
[TBL] [Abstract][Full Text] [Related]
7. The characteristics and mechanism of simvastatin loaded lipid nanoparticles to increase oral bioavailability in rats.
Zhang Z; Bu H; Gao Z; Huang Y; Gao F; Li Y
Int J Pharm; 2010 Jul; 394(1-2):147-53. PubMed ID: 20435111
[TBL] [Abstract][Full Text] [Related]
8. Effects of Silymarin on the In Vivo Pharmacokinetics of Simvastatin and Its Active Metabolite in Rats.
Li Y; Wu Y; Li YJ; Meng L; Ding CY; Dong ZJ
Molecules; 2019 Apr; 24(9):. PubMed ID: 31035343
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin.
Neuvonen PJ; Backman JT; Niemi M
Clin Pharmacokinet; 2008; 47(7):463-74. PubMed ID: 18563955
[TBL] [Abstract][Full Text] [Related]
10. A population pharmacokinetic model for simvastatin and its metabolites in children and adolescents.
Ogungbenro K; Wagner JB; Abdel-Rahman S; Leeder JS; Galetin A
Eur J Clin Pharmacol; 2019 Sep; 75(9):1227-1235. PubMed ID: 31172248
[TBL] [Abstract][Full Text] [Related]
11. Interconversion pharmacokinetics of simvastatin and its hydroxy acid in dogs: effects of gemfibrozil.
Prueksaritanont T; Qiu Y; Mu L; Michel K; Brunner J; Richards KM; Lin JH
Pharm Res; 2005 Jul; 22(7):1101-9. PubMed ID: 16028010
[TBL] [Abstract][Full Text] [Related]
12. Mechanistic studies on metabolic interactions between gemfibrozil and statins.
Prueksaritanont T; Zhao JJ; Ma B; Roadcap BA; Tang C; Qiu Y; Liu L; Lin JH; Pearson PG; Baillie TA
J Pharmacol Exp Ther; 2002 Jun; 301(3):1042-51. PubMed ID: 12023536
[TBL] [Abstract][Full Text] [Related]
13. Fevipiprant has a low risk of influencing co-medication pharmacokinetics: Impact on simvastatin and rosuvastatin in different SLCO1B1 genotypes.
Poller B; Woessner R; Barve A; Tillmann HC; Vemula J; Nica A; Elbast W; Schiller H; End P; Camenisch G; Weiss M
Pulm Pharmacol Ther; 2019 Aug; 57():101809. PubMed ID: 31195091
[TBL] [Abstract][Full Text] [Related]
14. Drug interactions with HMG-CoA reductase inhibitors (statins): the importance of CYP enzymes, transporters and pharmacogenetics.
Neuvonen PJ
Curr Opin Investig Drugs; 2010 Mar; 11(3):323-32. PubMed ID: 20178046
[TBL] [Abstract][Full Text] [Related]
15. Drug interactions with simvastatin.
Med Lett Drugs Ther; 2008 Oct; 50(1297):83-4. PubMed ID: 18927522
[No Abstract] [Full Text] [Related]
16. Effect of canagliflozin on the pharmacokinetics of glyburide, metformin, and simvastatin in healthy participants.
Devineni D; Manitpisitkul P; Murphy J; Skee D; Wajs E; Mamidi RN; Tian H; Vandebosch A; Wang SS; Verhaeghe T; Stieltjes H; Usiskin K
Clin Pharmacol Drug Dev; 2015; 4(3):226-36. PubMed ID: 27140803
[TBL] [Abstract][Full Text] [Related]
17. Development of a pharmacokinetic interaction model for co-administration of simvastatin and amlodipine.
Son H; Lee D; Lim LA; Jang SB; Roh H; Park K
Drug Metab Pharmacokinet; 2014; 29(2):120-8. PubMed ID: 23965645
[TBL] [Abstract][Full Text] [Related]
18. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.
Hubáček JA; Dlouhá D; Adámková V; Zlatohlavek L; Viklický O; Hrubá P; Češka R; Vrablík M
Med Sci Monit; 2015 May; 21():1454-9. PubMed ID: 25992810
[TBL] [Abstract][Full Text] [Related]
19. Genetic factors affecting statin concentrations and subsequent myopathy: a HuGENet systematic review.
Canestaro WJ; Austin MA; Thummel KE
Genet Med; 2014 Nov; 16(11):810-9. PubMed ID: 24810685
[TBL] [Abstract][Full Text] [Related]
20. Impact of SLCO1B1 Genotype on Pediatric Simvastatin Acid Pharmacokinetics.
Wagner JB; Abdel-Rahman S; Van Haandel L; Gaedigk A; Gaedigk R; Raghuveer G; Kauffman R; Leeder JS
J Clin Pharmacol; 2018 Jun; 58(6):823-833. PubMed ID: 29469964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
